Back to today’s briefing

Story perspectives

FDA Approves Lynkuet: New Hope for Menopause Relief

10/28/2025

28 4

Summary

Story summary

The U.S. Food and Drug Administration approved Lynkuet (elinzanetant), a hormone-free pill from Bayer, to treat moderate-to-severe menopause hot flashes.
Lynkuet works by blocking brain receptors that trigger hot flashes.
Clinical trials show a 73% reduction after 12 weeks.
Availability is set for November 2025, expanding options for about 80% of women with hot flashes.

1 of 1

Story summary

The U.S. Food and Drug Administration approved Lynkuet (elinzanetant), a hormone-free pill from Bayer, to treat moderate-to-severe menopause hot flashes.
Lynkuet works by blocking brain receptors that trigger hot flashes.
Clinical trials show a 73% reduction after 12 weeks.
Availability is set for November 2025, expanding options for about 80% of women with hot flashes.